The Journal of arthroplasty · 2024
Ulcerative Colitis Patients Are at Increased Risk for Adverse Events Following Total Hip Arthroplasty.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oghenesume Oghenewoma P, Gouzoulis Michael J, Ratnasamy Philip P, Dhodapkar Meera M, Grauer Jonathan N, Rubin Lee E
Аннотация
BACKGROUND: Patients who have the autoinflammatory bowel disease ulcerative colitis (UC) may become candidates for total hip arthroplasty (THA). Having UC may predispose patients to postoperative adverse events, but it remains unclear if these events are related more to the disease process itself or perhaps related to the medications used to treat the condition.
METHODS: Patients undergoing THA were identified from a large administrative dataset. Those who did not have and those who had UC were matched 4:1 based on patient age, sex, and the Elixhauser Comorbidity Index. Matched THA patients who did not have UC (n = 19,482) and those who had UC (n = 4,874) were identified. The matched groups were compared regarding 90-day adverse and five-year survival. Further analyses were performed based on classes of medications.
RESULTS: Controlling for patient age, sex, and Elixhauser Comorbidity Index, UC patients were at significantly higher odds of 90-day adverse events: any (odds ratio [OR]: 1.59), severe (OR: 1.72), and minor (OR: 1.63) (all P < 0.001). Despite this, no differences in 5-year survival were identified. Relative to those who did not have UC, there were increasing odds of any adverse event based on the potency of related medications: no corticosteroids/immunomodulators/5-aminosalicylic acid (5-ASA) (OR: 1.42), corticosteroids only (OR: 1.58), 5-ASA ± corticosteroids OR (1.72), and immunomodulators ± corticosteroids (OR: 1.74, all P < 0.001).
CONCLUSIONS: Total hip arthroplasty patients who have UC were at higher odds for 90-day postoperative adverse events relative to those who did not have UC, and this risk was even greater for those on defined classes of medications. Total hip arthroplasty patients who have UC bear specific considerations, and surgeons must carefully consider and manage the patient's medication regimen in the perioperative period of the THA.
METHODS: Patients undergoing THA were identified from a large administrative dataset. Those who did not have and those who had UC were matched 4:1 based on patient age, sex, and the Elixhauser Comorbidity Index. Matched THA patients who did not have UC (n = 19,482) and those who had UC (n = 4,874) were identified. The matched groups were compared regarding 90-day adverse and five-year survival. Further analyses were performed based on classes of medications.
RESULTS: Controlling for patient age, sex, and Elixhauser Comorbidity Index, UC patients were at significantly higher odds of 90-day adverse events: any (odds ratio [OR]: 1.59), severe (OR: 1.72), and minor (OR: 1.63) (all P < 0.001). Despite this, no differences in 5-year survival were identified. Relative to those who did not have UC, there were increasing odds of any adverse event based on the potency of related medications: no corticosteroids/immunomodulators/5-aminosalicylic acid (5-ASA) (OR: 1.42), corticosteroids only (OR: 1.58), 5-ASA ± corticosteroids OR (1.72), and immunomodulators ± corticosteroids (OR: 1.74, all P < 0.001).
CONCLUSIONS: Total hip arthroplasty patients who have UC were at higher odds for 90-day postoperative adverse events relative to those who did not have UC, and this risk was even greater for those on defined classes of medications. Total hip arthroplasty patients who have UC bear specific considerations, and surgeons must carefully consider and manage the patient's medication regimen in the perioperative period of the THA.